Publications by authors named "Mark Shahin"

Claim this Profile
C
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Mark S Shahin, Raina Mathur, Anju Parthan, Prakirthi Yerram, Amanda Kesner-Hays

Gynecol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.
Matthew A Powell, Line Bjørge, Lyndsay Willmott, Zoltán Novák, Destin Black, Mark S Shahin

Ther Adv Med Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilomatrix-like High-grade Endometrioid Carcinoma of the Uterine Corpus With Excellent Response to Immune Checkpoint Inhibitor Therapy.
Namra Ajmal, Olivia Nicolais, Mark S Shahin, Lucy Ma

Int J Gynecol Pathol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Mark S Shahin

Nat Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
Allan Covens, Helen Q Huang, Bradley J Monk, Yong-Beom Kim, Moon-Hong Kim, Mark S Shahin

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
Jeanne Carter, Helen Q Huang, Bradley J Monk, Yong-Beom Kim, Moon-Hong Kim, Mark Shahin

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Thierry André, Angela Jain, Mark S Shahin

Br J Clin Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small, Mark Shahin

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements, Danielle Enserro, Kyle C Strickland, Rebecca Previs, Daniela Matei, Mark Shahin

Gynecol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Mark S Shahin

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Matthew A Powell, David Cibula, David M O'Malley, Ingrid Boere, Mark S Shahin

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaginal lacerations during laparoscopic hysterectomy for endometrial cancer and local recurrence risk.
Olivia Nicolais, Mackenzie Cummings, Tommy R Buchanan, Lea Moukarzel, Nicholas Cardillo, Mark S Shahin

Gynecol Oncol Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
Amanda N Fader, Emily M Ko, Benjamin D Pollock, Stephanie V Blank, David E Cohn, Mark S Shahin

Gynecol Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
John K Chan, Chunqiao Tian, Joshua P Kesterson, Ken Y Lin, Kathleen Darcy, Mark Shahin

Gynecol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Roisin E O'Cearbhaill, Austin Miller, Robert A Soslow, Heather A Lankes, Deborah DeLair, Mark Shahin

Gynecol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Mark S Shahin

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Mark S Shahin

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
Stephanie V Blank, Warner K Huh, Maria Bell, Sarah Dilley, Melissa Hardesty, Mark Shahin

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Juvenile granulosa cell tumor in an adult woman during pregnancy: A case report and review of the literature.
Mackenzie Cummings, Pamela Edmonds, Mark S Shahin, Joel I Sorosky

Gynecol Oncol Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
Mario M Leitao, Qin C Zhou, Benny Brandt, Alexia Iasonos, Vasileios Sioulas, Mark Shahin

Gynecol Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, Ignacio Tusquets, Colleen McCormick, Mark S Shahin

Gynecol Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.
Mackenzie Cummings, Olivia Nicolais, Mark Shahin

Diagnostics (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Elizabeth M Swisher, Carol Aghajanian, David M O'Malley, Gini F Fleming, Scott H Kaufmann, Mark S Shahin

Gynecol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fighting for a Fair Day's Wage.
Mark Shahram Shahin

Obstet Gynecol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of an enhanced recovery protocol in gynecologic oncology.
Tanvi V Joshi, Shaina F Bruce, Rod Grim, Tommy Buchanan, Sudeshna Chatterjee-Paer, Mark S Shahin

Gynecol Oncol Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis